Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324335 · ClinicalTrials.gov registry record · Phase 2
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
A Phase 2 study, sponsored by Innovation Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02324335 is a Phase 2 study that has completed, run by Innovation Pharmaceuticals. The registered enrollment target is 61 participants.
The verdict
NCT02324335, a Phase 2 study, has completed, sponsored by Innovation Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation regimens used to treat cancer. This study examines the investigational drug brilacidin and its possible application in prevention of oral mucositis in patients undergoing chemoradiation for treatment of head and neck cancer.
Interventions
- OTHER Placebo
- DRUG Brilacidin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-08-14 |
| Est. Completion | 2017-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02324335
The ClinicalTrials.gov registry entry for NCT02324335 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innovation Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02324335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02324335 about?
NCT02324335 is a clinical study titled "Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer". Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation regimens used to treat cancer. This study examines the investigational drug brilacidin and its possible application in prevention of oral mucositis in patients undergoing chemoradiation for treatment of head ...
What is the current status of trial NCT02324335?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2014-08-14. Estimated completion is 2017-11-22.
What interventions are being tested in trial NCT02324335?
The interventions under investigation include: Placebo (OTHER), Brilacidin (DRUG).
Who is sponsoring clinical trial NCT02324335?
This trial is sponsored by Innovation Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.